BMS’ Commitment to Precision Medicine for Patients Living With Immune-Mediated Diseases
June 13, 2022
Originally published on Bristol Myers Squibb News & Perspectives
Kellie Calderon, MD, executive medical director at Bristol Myers Squibb, has built her career in both clinical practice as well as in the pharmaceutical industry. Through her experiences, she has learned the value of collaboration and the importance of precision medicine — both of which are vital in advancing treatments and care for people living with immune-mediated diseases.
Read the source article at CSRWire
2022-06-10 17:20:00